{"id":"clindamycin-benzoyl-peroxide-plus-adapalene","safety":{"commonSideEffects":[{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Peeling"},{"rate":null,"effect":"Irritation"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis, particularly against Cutibacterium acnes. Benzoyl peroxide generates reactive oxygen species that kill acne-causing bacteria and have keratolytic properties. Adapalene is a third-generation retinoid that binds retinoic acid receptors to normalize follicular keratinization and reduce comedone formation. Together, these agents address multiple pathogenic mechanisms of acne.","oneSentence":"This triple-combination topical treatment reduces acne through bacterial suppression (clindamycin), oxidative killing (benzoyl peroxide), and normalized skin cell turnover (adapalene).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:40.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT07205107","phase":"","title":"Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2025-10-02","conditions":"Acne Vulgaris","enrollment":200},{"nctId":"NCT05582434","phase":"EARLY_PHASE1","title":"Experience With Topical Acne Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-02-15","conditions":"Acne","enrollment":72},{"nctId":"NCT00671749","phase":"PHASE4","title":"Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-12","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT02557399","phase":"PHASE4","title":"DUAC® Early Onset Efficacy Study in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-07","conditions":"Acne Vulgaris","enrollment":350},{"nctId":"NCT01231334","phase":"PHASE4","title":"A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Acne Vulgaris","enrollment":286}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Duac® Topical Gel","Differin® 0.3% Gel"],"phase":"marketed","status":"active","brandName":"Clindamycin/benzoyl peroxide plus Adapalene","genericName":"Clindamycin/benzoyl peroxide plus Adapalene","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-combination topical treatment reduces acne through bacterial suppression (clindamycin), oxidative killing (benzoyl peroxide), and normalized skin cell turnover (adapalene). Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}